The Easter Island molecule that named a protein and became longevity's best-evidenced drug. Rapamycin is the register's longevity capstone, and it's overflowing with remarkable facts. A few: (1) it was found in soil bacteria on Easter Island (Rapa Nui) — and named after the island; (2) it's so central to cell biology that a master growth-regulating protein was named after it — mTOR = "mechanistic Target Of Rapamycin"; (3) it's the only drug proven to extend mammalian lifespan even when started in mid-life, replicated across three independent labs; (4) it's a paradox — a daily-dose immunosuppressant that, dosed weekly, may be geroprotective. It's a small molecule (approved drug), not a peptide — and human longevity proof still doesn't exist.
Rapamycin (sirolimus) is a small-molecule mTOR inhibitor — and longevity science's flagship. Discovered in soil bacteria on Easter Island (Rapa Nui) and named after the island, it's so fundamental that the master growth-sensing protein mTOR is named after it ("mechanistic Target Of Rapamycin"). It has lived four scientific lives — antifungal, then FDA-approved transplant immunosuppressant (1999), then anticancer, then the anti-aging frontier. Its landmark credential: in the 2009 NIA Interventions Testing Program (Nature), rapamycin extended the lifespan of already-old mice — replicated in three independent labs — making it the only drug proven to extend mammalian lifespan when started in mid-life, and the most reproducible lifespan extender across yeast, worms, flies, and mice. Mechanistically it inhibits mTOR, flipping cells from growth mode into repair mode (autophagy), reducing inflammation, and improving cellular housekeeping. The honest caveats: it's a potent prescription immunosuppressant, not a supplement; the longevity protocol (low weekly dosing) differs entirely from transplant dosing and aims to spare immunity; side effects are real; and — decisively — no human trial has yet demonstrated a longevity benefit (the PEARL RCT showed weekly dosing is reasonably safe, but durable functional benefits await replication). So: the best-evidenced longevity drug we have in animals, an approved and serious medicine, a molecule with a spectacular backstory — and still without human proof that it extends healthy lifespan.
an approved prescription drug (sirolimus) for transplant rejection and LAM. Longevity use is entirely off-label, requiring clinical oversight; there is no approved anti-aging indication.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.
We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Rapamycin (Sirolimus) changes - nothing else.
Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.
via PubChem exact-name match (Rapamycin) · high confidence
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.